Last reviewed · How we verify

Bupivacaine-fentanyl emergency group

Conrad Arnfinn Bjørshol · FDA-approved active Small molecule

Bupivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while fentanyl provides opioid analgesia by binding to mu opioid receptors.

Bupivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while fentanyl provides opioid analgesia by binding to mu opioid receptors. Used for Emergency anesthesia and analgesia, Acute pain management in emergency settings.

At a glance

Generic nameBupivacaine-fentanyl emergency group
SponsorConrad Arnfinn Bjørshol
Drug classLocal anesthetic + opioid analgesic combination
TargetVoltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
ModalitySmall molecule
Therapeutic areaAnesthesia, Emergency Medicine, Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that inhibits sodium influx into nerve cells, preventing depolarization and blocking pain signal transmission. Fentanyl is a potent synthetic opioid agonist that binds to mu opioid receptors in the central and peripheral nervous system to produce analgesia and sedation. This combination is used in emergency settings to provide rapid onset local anesthesia with concurrent systemic pain relief.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: